On 1 July, the Ministry of Health of Argentina reported the vaccine reduced deaths by 62% after the first dose and by 84% after the second dose. It was unknown how many people were included in the research. The study found no deaths related to COVID-19 in patients who received both doses. In April 2021, a study by the Abu Dhabi Public Health Centre found the vaccine was 93% effective in preventing hospitalization and 95% effective against admission to intensive care. While confident in its overall efficacy, WHO experts expressed very low confidence in their current ability to determine the safety of the BIBP vaccine for people with comorbidities, pregnant women, and the elderly as they were under-represented in the studies. Real-world test-negative analysis in Bahrain (based on 14 days post 2nd dose) indicated a vaccine effectiveness of 90% (95% CI, 88– 91%) for adults aged 18–59, and 91% ( 87– 94%) for those 60 year old or older. Effectiveness is generally expected to slowly decrease over time. EffectivenessĪ vaccine is generally considered effective if the estimate is ≥50% with a >30% lower limit of the 95% confidence interval. The World Health Organization (WHO) recommends an interval of 3 to 4 weeks between doses. The initial course consists of two doses, and there is no evidence that a third booster dose is needed. The vaccine is given by intramuscular injection into the deltoid muscle.

The similarly named Sinopharm WIBP COVID-19 vaccine is also an inactivated virus vaccine.Ī vaccination certificate of BBIBP-CorV (Beijing Institute of Biological Products, Sinopharm). Sinopharm has signed purchase agreements for 170 million doses from COVAX.

On, the World Health Organization approved the BIBP vaccine for use in COVAX. By May, Sinopharm had supplied 200 million doses. Sinopharm expects to produce one billion doses of the vaccine in 2021. The vaccine is being used in vaccination campaigns by certain countries in Asia, Africa, South America, and Europe. The BIBP vaccine could be transported and stored at normal refrigerated temperatures. While mRNA vaccines like the Pfizer–BioNTech COVID-19 vaccine and Moderna COVID-19 vaccine showed higher efficacy of over 90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. In December 2020, the UAE previously announced interim results showing 86% efficacy. Peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed that the vaccine is 78.1% effective against symptomatic cases and 100% against severe cases (21 cases in vaccinated group vs. Its product name is SARS-CoV-2 Vaccine (Vero Cell), not to be confused with the similar product name of CoronaVac. BBIBP-CorV shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants. The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, the Sinopharm COVID-19 vaccine, or BIBP vaccine, is one of two whole inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products (sometimes written as Beijing Bio-Institute of Biological Products, resulting in the two different acronyms BBIBP and BIBP for the same vaccine).

Atc vaccination times square pfizer